Insights Into the Pathogenicity of Rare Missense GCK Variants From the Identification and Functional Characterization of Compound Heterozygous and Double Mutations Inherited in Cis

Nicola L. Beer, dphil1,2
Kara K. Osbak, msc1
Martijn van de Bunt, md1
Nicholas D. Tribble, phd1
Anna M. Steele, msc3
Kirsty J. Wensley, pgcert3
Emma L. Edghill, phd3
Kevin Colough, bsc3

Amy Barrett, bsc1
Lucia Valentinova, msc1,5
Jana K. Rundle, phd1
Anne Raimondo, phd1
Joseph Grimsby, phd5
Sian Ellard, phd1,4
Anna L. Gloyn, dphil1,7

OBJECTIVE—To demonstrate the importance of using a combined genetic and functional approach to correctly interpret a genetic test for monogenic diabetes.

RESEARCH DESIGN AND METHODS—We identified three probands with a phenotype consistent with maturity-onset diabetes of the young (MODY) subtype GCK-MODY, in whom two potential pathogenic mutations were identified: [R43H/G68D], [E248 K/I225M], or [G261R/D217N]. Allele-specific PCR and cosegregation were used to determine phase. Single and double mutations were kinetically characterized.

RESULTS—The mutations occurred in cis (double mutants) in two probands and in trans in one proband. Functional studies of all double mutants revealed inactivating kinetics. The previously reported GCK-MODY mutations R43H and G68D were inherited from an affected father and unaffected mother, respectively. Both our functional and genetic studies support R43H as the cause of GCK-MODY and G68D as a neutral rare variant.

CONCLUSIONS—These data highlight the need for familyfunctional studies, even for previously reported pathogenic mutations.

Diabetes Care 35:1482–1484, 2012

A molecular diagnosis of monogenic diabetes is clinically important because there are implications for prognosis, treatment, and family members. Consequently, the correct interpretation of a molecular genetic test is paramount, but novel variants continue to be poorly characterized (1–3). As the cost of DNA sequencing falls, one of the major barriers to genetic testing will be removed and the correct assignment of pathogenicity to novel variants will become more challenging.

Heterozygous inactivating mutations in glucokinase (GCK) cause a subtype of maturity-onset diabetes of the young (GCK-MODY) (4), which is characterized by stable, mild fasting hyperglycemia, whereas homozygous or compound heterozygous inactivating mutations result in the more severe clinical phenotype of permanent neonatal diabetes mellitus (PNDM) (4). The opposite clinical phenotype of hyperinsulinemic hypoglycemia (GCK-HH) ensues from heterozygous activating mutations (4). In the current study, we explored the pathogenicity of six missense GCK mutations that were identified in combination in three probands referred for GCK-MODY molecular genetic testing. Our aim was to use both molecular genetics and functional studies to ensure correct interpretation of the genetic tests.

RESEARCH DESIGN AND METHODS

Subjects studied
All probands were referred to the U.K. diagnostic screening center for GCK-MODY testing, with corresponding clinical details given in Fig. 1. All subjects gave informed consent.

GCK screening and mutation identification
The pancreatic β-cell isoform of GCK (accession number NM_000162.3) was sequenced using standard protocols. Mutation testing was undertaken in family members to establish cosegregation and phase. Where parental DNA was unavailable, molecular haplotyping using allele-specific PCR was used to determine phase (primer sequences available upon request).

From the 1Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K.; the 2Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts; the 3Institute of Biomedical and Clinical Science, Peninsula Medical School, University of Exeter, Exeter, U.K.; the 4Molecular Genetics Department, Royal Devon and Exeter NHS Trust, Exeter, U.K.; the 5Institute of Experimental Endocrinology, Slovak Academy of Science, Bratislava, Slovakia; the 6Department of Metabolic Diseases, Hoffmann-La Roche Inc., Nutley, New Jersey; and the 7Oxford National Institute for Health Research, Churchill Hospital, Oxford, U.K. Corresponding author: Anna L. Gloyn, anna.gloyn@drl.ox.ac.uk. Received 13 December 2011 and accepted 9 March 2012. DOI: 10.2337/dc11-2420

This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-2420/-/DC1.

N.L.B. and K.K.O. contributed equally to this study.

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
CONCLUSIONS—Despite heterozygous inactivating GCK mutations being a well-established cause of MODY, the three probands in this study were unusual because mutational screening revealed that they each carried two mutations within this gene, thus raising questions about the pathogenicity of these variants and the correct interpretation of the molecular genetic tests. For two of the three probands, both mutations were present in cis. We demonstrated that three (E248K, I225M, and G621R) of these four variants were kinetically and individually sufficient to cause GCK-MODY, whereas the novel D217N variant showed no evidence of inactivation but instead was paradoxically activating due to increased glucose affinity. However, when studied in combination with G261R, the joint effect of both mutations resulted in a severe impact on enzyme function. Despite the deleterious effect on GCK activity caused by these mutations in cis, the mild clinical phenotype observed can be explained by compensation from GCK transcribed from the unaffected allele (13).

In contrast, the two previously reported GCK-MODY mutations R43H and G68D were present in trans, meaning the mild hyperglycemia observed could not easily
be explained because two inactivating mutations in trans should cause PNDM (4). Our family studies showed that R43H was inherited from the affected father and G68D from the unaffected mother, thus suggesting a pathogenic mutation and rare neutral variant, respectively. Consistent with these observations, our functional studies demonstrated that although R43H-GCK appeared to have similar basic kinetic characteristics to WT-GCK, there was in vitro evidence of protein instability, indicating that this variant is pathogenic. For G68D-GCK, there was no evidence of protein instability, and the very mild degree of kinetic activation was not predicted to cause hypoglycemia (Supplementary Table 1), supporting this as a rare neutral variant.

In conclusion, our study indicates that in silico evaluation is insufficient when assigning pathogenicity to rare nonsynonymous variants and demonstrates the need for both family and multi-tiered functional studies, even when dealing with previously reported “pathogenic” mutations.

Acknowledgments—This study was funded in Oxford by the Medical Research Council (81969), the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, and the Wellcome Trust (095101/Z/10/Z). The research leading to these results has also received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement 223211, CEED3. J.G. is employed by Hoffmann-La Roche. S.E. is employed as a core member of staff within the NIHR-funded Peninsula Clinical Research Facility. A.L.G. is a Wellcome Trust Senior Fellow in Basic Biomedical Science. No other potential conflicts of interest relevant to this article were reported.

N.L.B. and K.K.O. collected, analyzed, and interpreted data and wrote the manuscript. M.v.d.B. collected and analyzed data and critically reviewed the manuscript. N.D.T., E.L.E., K.C., A.B., L.V., J.K.R., and A.R. collected and analyzed data. A.M.S. and K.J.W. collected data. J.G. designed the study and critically reviewed the manuscript. S.E. conceived and designed the study and critically reviewed the manuscript. A.L.G. conceived and designed the study and wrote the manuscript. All authors approved the final version of the manuscript. A.L.G. is the guarantor of this study. M.v.d.B. is a Wellcome Trust Senior Fellow in Basic Biomedical Science. N.L.B. and K.K.O. collected, analyzed, and interpreted data.

References
1. Odem J, Munzinger E, Violand S, Van Morlan A, Rife D, Bachrach B. An infant with combination gene mutations for monogenic diabetes of youth (MODY) 2 and 4, presenting with diabetes mellitus requiring insulin (DMRI) at 8 months of age. Pediatr Diabetes 2009;10:550–553
2. Loomba-Albrecht LA, Jame M, Bremer AA. A novel glucokinase gene mutation and its effect on glycemia/C-peptide fluctuations in a patient with maturity-onset diabetes of the young type 2. Diabetes Res Clin Pract 2010;87:e23–e25
3. Rubio-Cabezas O. Diagnosing monogenic diabetes: common misinterpretations of genetic findings. Pediatr Diabetes 2009;10:497–499
4. Oshak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30:1512–1526
5. Davis EA, Cuesta-Muñoz A, Raoul M, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 1999;42:1175–1186
6. Beer NL, Tribble ND, McCulloch IJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009;18:4081–4088
7. Beer NL, van de Bunt M, Colclough K, et al. Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans. J Biol Chem 2011;286:19118–19126
8. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301:370–373
9. Kesavan P, Wang L, Davis E, et al. Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2). Biochem J 1997;322:57–63
10. Cuesta-Muñoz AL, Tuomi T, Cocho-Viñuelcier N, et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY). Diabetes Care 2010;33:290–292
11. Consortium TGP, 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061–1073
12. Burke CV, Buettger CW, Davis EA, McClane SJ, Matschinsky FM, Raper SE. Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinemia (GK-HI). Biochem J 1999;342:345–352
13. Liang Y, Najafi H, Smith RM, et al. Concordant glucose induction of glucokinase, glucose usage, and glucose-stimulated insulin release in pancreatic islets maintained in organ culture. Diabetes 1992;41:792–806